Trial Profile
A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel-group, International Multicenter Phase III Trial of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Muparfostat (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms PATRON
- Sponsors Medigen Biotechnology Corporation
- 12 Sep 2017 Primary endpoint (Disease-Free Survival (DFS)) has not been met as per the results presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 30 Mar 2016 Status changed from active, no longer recruiting to discontinued due to interim Analysis and business concerns, according to ClinicalTrials.gov record.